Boehringer In­gel­heim un­veils mid-stage win for glucagon/GLP-1 can­di­date for MASH, kin­dling PhI­II plans

Boehringer In­gel­heim said on Mon­day that its “dou­ble G” meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH) drug de­liv­ered pos­i­tive topline re­sults in a Phase II tri­al.

The com­pa­ny said that 83% of par­tic­i­pants in the sur­vo­du­tide arm passed the study’s biop­sy-dri­ven pri­ma­ry end­point, com­pared with 18.2% with place­bo (p<0.0001) at 48 weeks. Sur­vo­du­tide, which Boehringer “co-in­vent­ed” with Zealand Phar­ma, is a glucagon/GLP-1 re­cep­tor dual ag­o­nist ad­min­is­tered once week­ly via a sub­cu­ta­neous in­jec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER